**CURRICULUM VITAE**

**DATE PREPARED**: June 4, 2013

**PART I: General Information**

**Name:** Lorelei Ann Mucci

**Home Address:** 1103 Commonwealth Avenue

Newton, MA 02459 United States

**Office Address:** Harvard School of Public Health

Department of Epidemiology

677 Huntington Avenue, 9th floor

Boston, MA 02115 United States

**Phone:** (617) 432-1732

**Email:** lmucci@hsph.harvard.edu

**Fax:** (617) 566-7805

**Place of Birth:** Waltham, MA

**Education:**

1988 Certificate (Italian language and culture), American

Institute for Foreign Studies, Florence, Italy

1989 BS (Biology), Tufts University, Medford, MA

1997 MPH (Epidemiology and Biostatistics), Boston University

School of Public Health, Boston, MA

2003 ScD (Epidemiology), Harvard School of Public Health,

Boston, MA

**Postdoctoral Training:**

2002-2003 Research Fellow in Epidemiology, Karolinska Institutet,

Stockholm, Sweden

2003-2005 Research Fellow in Cancer Epidemiology, Harvard School of

Public Health, Boston, MA

**Academic Appointments:**

1998-2002 Graduate Research Assistant in Epidemiology, Harvard School

of Public Health, Boston, MA

1998-2002 Graduate Research Assistant in Oral Health Policy and

Epidemiology, Harvard School of Dental Medicine, Boston, MA

2000-2002 Graduate Research Assistant in Medical Epidemiology,

Karolinska Institutet, Stockholm, Sweden

2002-2003 Research Fellow in Epidemiology, Karolinska Institutet,

Stockholm, Sweden

2003-2005 Research Fellow in Cancer Epidemiology, Harvard School of

Public Health, Boston, MA

2003-2006 Instructor of Medicine, Harvard Medical School, Boston,

MA

2006-2010 Assistant Professor in the Department of Epidemiology, Harvard School of Public Health, Boston, MA

2006- Assistant Professor of Medicine, Harvard Medical School, Boston,

MA

2010- Associate Professor of Epidemiology, Harvard School of Public Health, Boston MA

**Hospital or Affiliated Institution Appointments:**

2003- Associate Epidemiologist, Brigham and Women's Hospital,

Boston, MA

**Other Professional Positions and Major Visiting Appointments:**

1997 Graduate Research Internship, Boston University School of

Public Health, Boston, MA

1997-2002 Senior Research Analyst, Bureau of Health Statistics,

Research and Evaluation, Massachusetts Department of Public Health, Boston, MA

2004 Instructor, Boston University School of Public Health, Boston, MA

2008- Visiting Professor of Public Health, University of Iceland, Reykjavik, Iceland

2012- Foreign Visiting Professor, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden

**Major Administrative Responsibilities:**

2005- Co-Director, Channing Peer-Mentoring Program for 40 Post-Doctoral Fellows and Instructors, Channing Laboratory, BWH

2005-7 Organizer, Channing Seminar Series, Chronic Disease Epidemiology Group, Channing Laboratory, BWH

2006- Admissions Committee, Epidemiology Department, Harvard School of Public Health

1. Member, Dana Farber/Harvard Cancer Center, Boston, MA

2006- Member and Project Co-Leader, Dana Farber Prostate Cancer SPORE, Boston MA

* 1. Science Advisory Board, Environmental Protection Agency, Acrylamide Review Panel

2007-8 Organizer, Epidemiology Department Seminar Series, Harvard School of Public Health

2007-10 Gender Equality Committee, Epidemiology Department, Harvard School of Public Health

2009- Scientific Advisory Board, Pathology Cores, Dana Farber/Harvard Cancer Center

2010- Faculty Mentor, Nutrition and Cancer Training Grant, Harvard School of Public Health

2010 Grant Review Panel, World Cancer Research Fund

2010- Scientific Advisory Board, Tissue Studies, Nurses Health Study

2010- Standing Review Committee, Prostate Cancer Foundation Research Awards

2010- Review Committee, Harvard School of Public Health Post-doctoral Travel Scholarship Awards

2010- Scientific Advisory Board, Prostate Cancer Foundation

2011- Grant Review Committee, David Mazzone, Dana-Farber/Harvard Cancer Center Prostate SPORE

2011- Grant Review Committee, The Prostate Cancer Charity UK Research Awards

2011- Grant Review Committee, Prostate Cancer Foundation of Australia

2011- Post-doctoral Fellow Advisory Committee, Harvard School of Public Health

2011- Epidemiology Department Seminar Series, Harvard School of Public Health

2011- Movember USA Global Action Plan Team Member, Prostate Cancer Foundation

2011- Head of Cancer Epidemiology Concentration, Harvard School of Public Health

2011- Co-Leader of Cancer Epidemiology Program, Dana Farber/Harvard Cancer Center

2012- Ad Hoc Member, Epidemiology of Cancer (EPIC) Study Section, National Institutes of Health/National Cancer Institute

2012 Ad Hoc Member, Special Study Section: Provocative Questions, National Institutes of Health/National Cancer Institute

2012 Grant Review Committee, Dana Farber/Harvard Cancer Center U54 Pilot Applications

2013 Grant Review Committee, Health Research Board of Ireland

2013 Grant Review Committee, Irish Cancer Society Career Development Awards

2013- Harvard School of Public Health Disciplinary Board

**Professional Societies:**

2001-5 Society for Epidemiological Research, Member

2003- American Association for Cancer Research, Associate Member

**Journals:**

2003- Ad-Hoc Reviewer, International Journal of Cancer

2004- Ad-Hoc Reviewer, Cancer Causes and Control

2004- Ad-Hoc Reviewer, Cancer Epidemiology, Biomarkers and

Prevention

2005- Ad-Hoc Reviewer, Journal of the National Cancer

Institute

* 1. Ad-Hoc Reviewer, Journal of Food Composition and Analysis

2006-2008 Editorial Board, Menopause

* 1. Editorial Board, The Open Epidemiology Journal

1. Ad-Hoc Reviewer, Clinical Cancer Research

2008- Ad-Hoc Reviewer, American Journal of Pathology

1. Ad-Hoc Reviewer, Cancer Research

2009- Associate Editor, Cancer Causes Control

2010- Ad-Hoc Reviewer, Lancet Oncology

2011- Editorial Board, Clinical Genitourinary Cancer

2011- Ad-Hoc Reviewer, British Journal of Urology International

**Awards and Honors:**

2003- 10 NIH Loan Repayment Program Award, National Institutes of

Health

2003 James M. Dunning Award for Research Excellence,

Harvard School of Dental Medicine

2005 American Society for Clinical Oncology Merit Award,

American Society for Clinical Oncology

1. American Cancer Society Travel Scholarship, ACS
2. Harvard Dependent Care Fund Award
   1. Michael Milken Scholar, Prostate Cancer Foundation
3. Top Performing Young Investigator, Prostate Cancer Foundation

2010 Harvard Dependent Care Fund Award

**Part II: Research, Teaching, and Clinical Contributions**

**A. Narrative report of Research and Teaching**

My major research focuses on the epidemiology of prostate cancer risk and progression within cohorts of men from the United States and Scandinavia, with an emphasis on cancer biomarker studies, including circulating markers, inherited genetic alleles, as well as tumor biomarkers.

**Pathoepidemiology of prostate cancer**. I co-lead the Prostate Cancer Patho-epidemiology team, a multidisciplinary effort that integrates pathology data and tumor biomarkers at the RNA, DNA and protein level into our epidemiological studies. The overarching objective of this work is to identify molecular signatures of lethal prostate cancer and response to therapy, and provide insight into the biology of prostate cancer risk factors and progression.  The projects leverage a tumor biorepository of 3,000 men with prostate cancer from the Physicians Health Study (PHS), Health Professionals Follow-up Study (HPFS), and a Swedish Watchful Waiting Cohort.  The US and Swedish projects are undertaken in concert with the DF/HCC Prostate Cancer SPORE, of which I am an active participant and from which I have received multiple research awards.

**Twin studies of cancer**. I am co-PI of a large-scale twin study of cancer among 300,000 twins from Sweden, Norway, Denmark and Finland. Within this unique resource, we aim to estimate the heritability in risk of various cancers, as well as to examine the relative contributions of genetic and environmental factors in cancer survival.  Future work in the twin setting will include a tumor tissue collection, in order to examine the heritability of somatic alterations in tumors.

**Walking group intervention study**. The main goal of treating men with high-risk prostate cancer is to improve cancer survival.  At the same time, cardiovascular and other chronic diseases represent half of causes of death among men with locally advanced tumors, while men with prostate cancer experience impairments in physical and mental quality of life, both from the cancer as well as from therapy.  Considering the patient holistically, the identification of lifestyle interventions that could improve survival, enhance the efficacy of therapeutic interventions, as well as improve overall health and quality of life would provide maximum benefit to men.  Physical activity post-diagnosis may represent such an intervention.  We recently completed a pilot study of a group walking intervention, whereby men were randomized to either usual care or SPARTACUS, a walking intervention of weekly group walks and were encouraged to maintain 10,000 steps per day on other days.  We are now planning a larger scale trial in Sweden and Iceland. Our overarching premise is that 1-) a cancer diagnosis represents a teachable moment when men are amenable to lifestyle change, 2-) walking represents a low cost physical activity sustainable throughout life, and 3-) a group environment provides men with an opportunity to discuss issues related to their cancer.

**Prostate cancer in Iceland** I am involved in a broad range of research projects on prostate cancer within The Reykjavik Study, a population-based cohort of men from Iceland.  These projects include the utilizing the unique dataset to study the role of early life diet on prostate cancer risk. In addition, I am leading up a project to investigate the sleep-melatonin hypothesis in prostate cancer using urinary biomarkers and measures of the pineal gland. I am a Visiting Professor at the University of Iceland, and supervise 1 doctoral student.

**Teaching.** Teaching has been a core activity for me over the past 8 years. I co-lead two HSPH based courses, Epidemiology of Cancer (EPI213) and Practice of Epidemiology (EPI205). I guest lecture in several HSPH courses, and I also co-lead a two-week bootcamp course at HMS entitled the Molecular Pathology and Epidemiology of Cancer for the graduate students. Additional mentoring activities include formal mentoring of doctoral and MPH students, working on research projects with clinical fellows in urology and radiation oncology at the Harvard teaching hospitals, and working with students and fellows through my role as head of the cancer epidemiology program at HSPH.

**B. Funding Information**

2002-2008 Co-Investigator, N.I.H., R01CA090598, Growth Factors and

Prostate Cancer Risk

2003-2006 Investigator, D.O.D., PC031057, Department of Defense Idea

Development Award, A Population-Based Study of Dietary Acrylamide and Prostate Cancer Risk

2004-2007 P.I., Dana Farber/Harvard Cancer Center Prostate SPORE,

Career Development Award, "A Composite Biomarker for Prostate Cancer Death"

2005-2008 Investigator, D.O.D., PC040715, Department of Defense Idea

Development Award, Identification of Aggressive Prostate Cancer using SNP Analysis

2005-2008 P.I., D.O.D., PC050696, Department of Defense New

Investigator Award, Molecular and Clinical Predictors of Aggressive Prostate Cancer

2006-2007 PI, DF/HCC Prostate SPORE Development Award, “Biomarkers of Angiogenesis and Development of Lethal Prostate Cancer”

2007-2010 Investigator, Department of Defense Idea Development Award, “The Infectious Pathogenesis of Prostate Cancer”

2007-2009 PI, Harvard William F. Milton Fund, “Infectious origins of prostate cancer”

2007-2009 PI, DF/HCC Prostate SPORE Developmental Project Award, “Genetic variation and the TMPRSS2:ETS fusion in prostate pathogenesis”

2008-2011 PI, Prostate Cancer Foundation Young Investigators Award, “Do dietary and lifestyle factors interact with the TMPRSS2:ERG fusion to predict progression”

2008-2013 Co-Investigator, NIH/NCI R01CA131945, “Metabolic syndrome, fatty acid synthase, and prostate cancer”

2008-2009 Co-Investigator, DF/HCC Prostate SPORE Developmental Project Award, NIH/NCI P50 CA90381, “Dietary phytoestrogens in relation to prostate cancer risk and progression”

2008-2009 Co-Mentor, DF/HCC Prostate SPORE Career Development Award (Stark), NIH/NCI P50 CA90381, “Proliferative inflammatory atrophy in prostate cancer: a patho-epidemiology study”

2008-2013 PI, Ellison Foundation, “Genetic and environmental contributions to cancer etiology and progression among 150,000 Nordic Twins”

2009-2014 PI, NIH/NCI RO1 CA136578-01, “Sex hormones and the TMPRSS2:ERG fusion in prostate cancer progression”

2009-2012 PI, DF/HCC Prostate SPORE Full Project Award, NIH/NCI P50 CA90381, “*TMPRSS2:ERG* and SPINK1 in Lethal Prostate Cancer”

2010-2015 Co-Investigator, NIH/NCI RO1 “Growth factors and lethal prostate cancer”

2010-2013 Principal Investigator, US Army Prostate Cancer Program Idea Development Award, “BRCA1 and Lethal Prostate Cancer”

2010-2013 Mentor, Icelandic RANNIS Foundation – Lara Siguradottir, “Melatonin and Prostate Cancer”

2010-2012 PI Subcontract, DF/HCC Prostate SPORE Full Project Award, NIH/NCI P50 CA90381, “Biguanides for the treatment of prostate cancer”

2010-2011 Principal Investigator, Harvard Catalyst Pilot Awards, “Melatonin and Prostate Cancer: A biomarker study among men in the Reykjavik Cohort”

2011-2014 PI Subcontract, US Army Prostate Cancer Impact Award, PC101749 - "A Systems Biology Approach to Link Nuclear Factor Kappa B Activation with Lethal Prostate Cancer”

2010-2011 PI Subcontract, NIH/NCI, “Antioxidant Pathways and Prostate Cancer Risk”

2011-2013 Mentor, DF/HCC SPORE in Prostate Cancer Mazzone Career Development Award, “Phosphorus and calcium intake, tumor microenvironment and prostate cancer progression”

2012-2015 PI Subcontract, US Army Prostate Cancer Program Impact Award, “Telomere length and lethal prostate cancer”

2011-2016 Collaborator, Harvard University Trandisciplinary Research in Energetics and Cancer (TREC), NCI/NIH

2011-2012 Mentor, Rose International Traveling Fellowship – Sarah Coseo Markt, “Sleep, melatonin and prostate cancer in Iceland”

2012-2013 Mentor, US Army Prostate Cancer Research Program Post-doctoral Fellowship-Julie Kasperzyk, “Prostate Cancer Tumor Heterogeneity”

2012-2015 Co-Investigator, US Army Idea Development Award, “De novo lipogenesis, fat intake and prostate cancer survival”

2012-2013 Principal Investigator, Dana Farber/Harvard Cancer Center Mazzone Awards Program Disparities Research Mechanism, “Estimating the Prostate Cancer Burden attributed to Lifestyle and Genetic Factors among African-American and White Men”

2012-2014 Co-PI, Prostate Cancer Foundation Challenge Award, “Shedding light on stromal-epithelial interactions in prostate cancer carcinogenesis and mortality”

2012-2015 Mentor, Prostate Cancer Foundation Young Investigator Award– Stephen Finn, “Identifying non-coding RNA repertoires of aggressive prostate cancer”

2012-2014 Mentor, Urology Care Foundation Research Scholar Program – Mark Preston, “Association between Finasteride and High-grade or Lethal Prostate Cancer”

2012-2013 Mentor, Rose International Traveling Fellowship – Irene Shui, “Prostate cancer in Ireland”

2013-2018 Co-Investigator, NIH/NCI RO1, Bioinformatics Tools for Genomic Analysis of Tumor and Stromal Pathways in Cancer

2013-2016 Mentor, Prostate Cancer Foundation Young Investigator Award – Jennifer Rider, “The Immunomodulatory and Androgen-Associated Actions of Vitamin D in Prostate Cancer”

**C. Report of Teaching**

**1. Local contributions**

**a. Graduate Medical Courses**

1998 Introduction to Epidemiology, Boston University School

of Public Health

*contact time prep time*

Teaching 100 Graduate 40 hours/year 120 hours/year

Assistant Students for 1 year(s) for 1 year(s)

1998-2000 Infectious Disease Epidemiology, Boston University School of

Public Health

*contact time prep time*

Teaching 35 Graduate 25 hours/year 55 hours/year

Assistant Students for 1 year(s) for 1 year(s)

1999 Introduction to Epidemiology, Harvard School of Public

Health

*contact time prep time*

Teaching 110 Graduate 25 hours/year 55 hours/year

Assistant Students for 1 year(s) for 1 year(s)

1999-2002 Epidemiology of Infectious Disease, Harvard School of Public

Health

*contact time prep time*

Teaching 60 Graduate 25 hours/year 55 hours/year

Assistant Students for 1 year(s) for 1 year(s)

2000-2001 Epidemiological Analysis of Outbreaks and Infectious Disease,

Harvard School of Public Health

*contact time prep time*

Teaching 60 Graduate 25 hours/year 55 hours/year

Assistant Students for 1 year(s) for 1 year(s)

2000-2002 Epidemiology of HIV/AIDS, Harvard School of Public Health

*contact time prep time*

Senior Teaching 40 Graduate 25 hours/year 75 hours/year

Assistant Students for 1 year(s) for 1 year(s)

2000-2002 Analysis of Case-control and Cohort Studies, Harvard School

of Public Health

*contact time prep time*

Senior Teaching 90 Graduate 40 hours/year 120 hours/year

Assistant Students for 1 year(s) for 1 year(s)

2001-2002 Epidemiology of Infectious Disease, Harvard School of Public

Health

*contact time prep time*

Senior Teaching 60 Graduate 40 hours/year 120 hours/year

Assistant Students for 1 year(s) for 1 year(s)

2003 Design Issues in Epidemiology, Boston University School

of Public Health

*contact time prep time*

Lecturer 8 Graduate 3 hours/year 15 hours/year

Students for 1 year(s) for 1 year(s)

2004 Cancer Epidemiology, Boston University School of Public

Health

*contact time prep time*

Course Instructor 10 Graduate 40 hours/year 120 hours/year

/Director Students for 1 year(s) for 1 year(s)

2004-2005 Cancer Prevention, Harvard School of Public Health

*contact time prep time*

Lecturer 45 Graduate 3 hours/year 25 hours/year

Students for 1 year(s) for 1 year(s)

2005 Advanced Topics in Cancer Epidemiology, Harvard School

of Public Health

*contact time prep time*

Course Instructor 10 Graduate 20 hours/year 60 hours/year

Students for 1 year(s) for 1 year(s)

2006-2007 Screening, Harvard School of Public Health

*contact time prep time*

Course Instructor 70 Graduate 32 hours/year 160 hours/year

2006-pres Applied Biomarkers in Cancer Epidemiology, Harvard School of Public Health

*contact time prep time*

Lecturer 30 Graduate 2 hours/year 10 hours/year

2007- pres Practice of Epidemiology, Harvard School of Public Health

*contact time prep time*

Course Instructor 20 Graduate 32 hours/year 160 hours/year

2007- pres Cancer Epidemiology, Harvard School of Public Health

*contact time prep time*

Course Instructor 30 Graduate 32 hours/year 160 hours/year

2009 Nutritional Epidemiology of Cancer, Harvard School of Public Health

Guest Lecturer 15 Graduate 2 hours/year 20 hours/year

2010 Molecular Pathology Bootcamp, Harvard Medical School

Guest Lecturer 10 Graduate 2 hours/year 20 hours/year

2011-pres Molecular Pathology and Epidemiology Bootcamp, Harvard Medical School

Co-course Leader 15 Graduate 25 hours/year 30 hours/year

2012-2013 Clinical Epidemiology, Clinical Effectiveness Program, Harvard School of Public Health Guest Lecturer

2012-2013 PH207x. Health in Numbers: Quantitative Methods in Clinical and Public Health Research, edX of Harvard and MIT Guest Lecturer

**b. Local Invited Presentations**

**Invited Seminar/Panels**

2004 Molecular Signatures of Prostate Cancer Survival, Harvard

School of Public Health

2004 Plasma Levels of Free IGF-1, Acid-labile Subunit and Prostate

Cancer Risk: A Prospective Study, Channing Laboratory/Brigham and Women's Hospital

2006 Microvessel Density and architecture: biomarkers of lethal prostate cancer, Harvard Prostate Cancer Working Group, HSPH

2006 Molecular signatures to predict lethal and indolent prostate cancer, BWH-BRI Inaugural Cancer Research Center Retreat

2007 Biomarkers of tumor angiogenesis and lethal prostate cancer, Dana Farber Harvard Cancer Center Prostate SPORE Meeting, Boston

2007 Incorporating tumor biomarkers into cancer epidemiology studies: the prostate cancer story, Department of Epidemiology Seminar Series, Harvard School of Public Health

2008 Genetic susceptibility and the *TMPRSS2:ERG* fusion, Dana Farber Harvard Cancer Center SPORE Meeting, DFCI

1. Dietary and biochemical predictors of prostate cancer risk and progression, the Harvard Urology and Prostate Cancer Seminar Series, Harvard Institute of Medicine

2008 Invited Panelist, Work and Family Balance Panel, Office for Women’s Careers, Brigham and Women’s Hospital

2008 Invited Panelist, Women in Academe: Balancing Family and Careers, Harvard School of Public Health

2008 Prostate Tumor Biomarker Studies in the Health Professionals Follow-up Study, Health Professionals Follow-up Study External Advisory Board Meeting, Harvard School of Public Health

2008 The *TMPRSS2:ERG* fusion and the sex hormone milieu, Dana Farber Harvard Cancer Center SPORE Meeting, DFCI

2009 The *TMPRSS2:ERG* fusion in prostate cancer, Molecular Epidemiology Working Group Seminar, Harvard School of Public Health

2009 Prostate Cancer Epidemiology and the *TMPRSS2:ERG* fusion, Dana Farber/Harvard Cancer Center’s Conference on Cancer

2009 Translocations and Aberrations: a patho-epidemiology study of prostate cancer risk and progression, Epidemiology Seminar, Harvard School of Public Health

2009 *TMPRSS2:ERG* and SPINK1 in Lethal Prostate Cancer, Dana Farber/ Harvard Cancer Center Prostate SPORE, External Advisory Board Meeting

2011 TMPRSS2:ERG, SPINK1 and Lethal Prostate Cancer, Dana Farber/Harvard Cancer Center Prostate SPORE Meeting

2011 The Burden of Cancer from an Epidemiologist’s Perspective, Summer Program in Quantitative Methods, Harvard School of Public Health

### 2011 Future Directions for Translation of Archival Tissue Studies (Panel Discussion). **Emerging Technologies for Translation Bioinformatics: A symposium on gene expression profiling for archival tissues, Harvard School of Public Health**

2011 Shedding Light on the Heritability of Cancer: a study of 200,000 Nordic Twins, Department of Epidemiology Seminar Series, Harvard School of Public Health

2012 Cancer: what have we learned and where do we go from here? Harvard School of Public Health Leadership Council Meeting

2012 Unveiling the potential of patho-epidemiology to understand prostate cancer, Quantitative Issues in Cancer Research Working Seminar, Department of Biostatistics, Harvard School of Public Health

2013 Exploring Mechanisms Underlying the Link between Obesity, Physical Activity and Lethal Prostate Cancer, Harvard Transdisciplnary Research in Energetics and Cancer Annual Meeting

2013 Dana Farber/Harvard Cancer Center Scientific Council Meeting, Tumor/Patient Genotyping Efforts within DF/HCC

**c. Advisory and Supervisory Responsibilities in Clinical or Laboratory Setting**

2005-6 1 Graduate Student for 25 hrs/year, Supervisor,

Karolinska Institutet, Stockholm, Sweden

2005- 8 Doctoral Students for 125 hrs/year, Supervisor/Thesis Committee,

Harvard School of Public Health

2006- 3 Master of Science Students for 15 hrs/year, Academic Advisor, Harvard School of Public Health

2006- 5 Post-doctoral Fellows for 75 hrs/year, Supervisor, Channing Laboratory, BWH/Harvard Medical School

2006-10 40 Post-doctoral Fellows/Instructors for 100 hrs/year, Peer-Mentor, Channing Laboratory, BWH/Harvard Medical School

1. 3 Radiation Oncology Fellows for 25 hours/year, Co-Mentor

Brigham and Women’s Hospital/HSPH

**d. Leadership Roles**

2003-6 Organizer, Harvard Prostate Cancer Molecular Epidemiology Working Group, HSPH/DFCI/BIDMC/BWH

Responsibility: I organize and develop the agenda for the monthly meetings of the Harvard Prostate Cancer Working Group, including developing ideas and themes for group discussion and arranging speakers.

2004- Organizer and Advisory Member, Scandinavian-US

Prostate Cancer Collaborative and Summit, Harvard University and Karolinska Institutet

Responsibility: I am directing the epidemiology activities around our collaborative projects on molecular markers of indolent and aggressive prostate cancer between research institutes in the US and Sweden, and I am a member of the Advisory Group overseeing the collaboration. I also was an organizer for the first Scandanavian-US Prostate Cancer Summit held in September 2005 in the Stockholm archipelago in which we discussed the research agenda for the upcoming year.

2005-11 Director, Channing Peer Mentoring, BWH/HMS

Responsibility: I supervise the peer mentoring activities for 40 post-doctoral fellows and Instructors affiliated with the Channing Laboratory, and am directly responsible for mentoring of 13 individuals. I helped to develop this program in order to improve the post-doctoral experience, and provide additional mentorship. I meet twice per year with the fellows, and as needed, and provide guidance on a diverse array of issues.

2006 Harvard Medical School Leadership Development for Physicians and Scientists, Harvard Medical School Course

2006- Member, Dana-Farber/Harvard Cancer Center Cancer Epidemiology Program and Prostate Cancer Program

2008 Organizer, Dana-Farber/Harvard Cancer Center Interdisciplinary Workshop: Incorporating novel tumor tissue analysis into population based studies of human cancer, Harvard Medical School. Organized speakers and scientific program for one day workshop on tumor tissue markers through the DFHCC

2009 Science Fair Judge, New England Science Symposium, Harvard Medical School. Served as Judge of Poster Session at this annual graduate student research symposium sponsored by the Harvard Medical School Minority Faculty Development Program of the Office of Diversity and Community Partnership

2009- Advisory Board Member, Nurses Health Study Tissue Laboratory, Channing Laboratory, Brigham and Women’s Hospital

2010- Faculty Advisor, T32 Nutrition and Cancer Training Grant, Department of Epidemiology, Harvard School of Public Health

2010- Scientific Advisory Board, Prostate Cancer Foundation

2011- Member, Harvard School of Public Health Postdoc Advisory Committee

2012- Member, Movember Global Action Plan

2012- Head, Cancer Epidemiology Area of Concentration, Harvard School of Public Health

2012- Co-Leader, Cancer Epidemiology Program, Dana Farber/Harvard Cancer Center

2012 Workshop organizer, mRNA profiling pilot studies in the Harvard Cohorts, Dana Farber/Harvard Cancer Center

2012- Member, Admissions and Financial Aid Committee, Department of Epidemiology, Harvard School of Public Health

2012- Co-Leader, Prostate Cancer Foundation “School of Public Health”

2013 Organizer, Dana Farber/Harvard Cancer Center, Celebration of Young Investigators in Cancer Research. Organized a half-day symposium of 80 people to celebrate the accomplishments and research of young investigators working in population science across the DF/HCC

**e. Advisees/Trainees**

*Training Duration Name Current Position*

2004-6 Hayley Hunt Doctoral Student

2004-7 Katja Fall Post-doctoral Fellow

2004-6 Stephanie Bakaysa MPH Student

2005- Christine Jesser Doctoral Student (Primary Mentor)

2005-8 Jennifer Stark Doctoral Student (Secondary Mentor)

2005-8 Kathryn Wilson Doctoral Student (Secondary Mentor)

2006-9 Julie Kasperzyk Doctoral Student (Thesis Committee)

2006-9 Kathryn Penney Doctoral Student (Thesis Committee)

2006-7 Patravoot Vatanasapt Masters of Science Student (Advisor)

2007- Aditi Hazra Postdoctoral Fellow (Secondary Mentor)

2007 Justin Manjourees Doctoral Student (Oral Committee)

2007-8 Ioannis Rigas MPH Student (Advisor)

2007-8 Julia Hayes MPH Student (Advisor)

2007-11 Irene Shui Doctoral Student (Advisor)

2007- Mara Meyer Doctoral Student (Advisor)

2008- Matthew Austin Doctoral Student (Oral Committee)

2008-11 Kathryn Wilson Post-doctoral Fellow (Mentor)

2008-11 Jennifer Stark Post-doctoral Fellow (Mentor)

2008 Keerthana Gnanapradeepan Continuing Umbrella of Research Experience (CURE) (Mentor)

2008- David Wheeler MPH Student (Advisor)

2008- Shih-Wen Lin MPH Student (Advisor)

2008- Michaela Cada MPH Student (Advisor)

2009 Blaine Thomas HMS Student (Summer Project Advisor)

2009- Lara Sigurdardottir PhD Student (University of Iceland; Co-

Mentor)

2009- Wang Xiang Doctoral Student (Advisor)

2009- Rebecca Graff Doctoral Student (Advisor)

2009-10 Danielle Margalit MPH Student/Clinical Fellow (Mentor)

2009-10 Annette Kaufman MPH Student (Advisor)

2010- Elisabete Moller Doctoral Student (Karolinska Institutet; Co-Supervisor)

2010-2 Andreas Pettersson Post-doctoral Fellow (Mentor)

2010-2 Mara Meyer Post-doctoral Fellow (Mentor)

2010- Sarah Coseo Markt Doctoral Student (Advisor)

2010-11 Piotr Zareba MPH Student (Advisor)

2010-11 Tryggvi Thorgeirsson MPH Student (Advisor)

2010-2 Jennifer Sinnott Doctoral Student (Oral and Thesis Committee)

2011-2 Henry Park MPH Student (Advisor)

2011- Jennifer Rider Instructor/Assistant Prof (Faculty mentor)

2011-3 Jonathan Schoenfeld MPH Student/Clinical Fellow (Mentor/Research advising)

2011- Kathryn Wilson Research Associate (Mentor)

2011-2 Yen Chien MPH Student (Advisor)

2011-2 Sun Yi Moo MPH Student (Advisor)

2010- Ke Zu Doctoral Student (Oral and Thesis Committee)

2011- Mark Preston Clinical Fellow at MGH (Research advising)

2012 Gregory Judson MD student at Columbia (Faculty Mentor)

2012 Ran Zhang Doctoral Student (Oral Committee)

2012- Thomas Ahearn Post-doctoral Fellow (Mentor)

2012- Ericka Noonan Post-doctoral Fellow (Mentor)

2012- Travis Gerke Pre-doctoral Fellow (Mentor)

2012- Jennifer Sinnott Post-doctoral Fellow (Co-Mentor)

2012-3 Ardalan Ebrahimi MPH Student (Advisor)

**2. Regional, national, or international contributions**

**a. Graduate Medical Courses**

*International*

2006 Cancer Epidemiology and Biomarkers, Modern Methods in Biostatistics and Epidemiology, Cison di Valmarino, Italy

*contact time prep time*

Course Instructor 12 Graduate 20 hours/year 60 hours/year

/Director Students for 1 year(s) for 1 year(s)

2007 Design and Analysis of Case-control Studies, Modern Methods in Biostatistics and Epidemiology, Cison di Valmarino, Italy

*contact time prep time*

Course Instructor 15 Graduate 20 hours/year 60 hours/year

/Director Students for 1 year(s) for 1 year(s)

2008 Design of Case-control Studies and Cohort, Modern Methods in Biostatistics and Epidemiology, Cison di Valmarino, Italy

*contact time prep time*

Course Instructor 20 Graduate 20 hours/year 60 hours/year

/Director Students for 1 year(s) for 1 year(s)

2009 Design of Case-control Studies and Cohort, Modern Methods in Biostatistics and Epidemiology, University of Iceland, Reykjavik, Iceland

*contact time prep time*

Course Instructor 25 Graduate 20 hours/year 60 hours/year

/Director Students for 1 year(s) for 1 year(s)

2011 Translational Research using Bioinformatics and Epidemiology, Kings College, London, UK

*contact time prep time*

Course Instructor 35 Graduate 10 hours/year 20 hours/year

Students for 1 year(s) for 1 year(s)

2012 Study Design in Epidemiology Research: Case-control studies, University of Iceland, Reykjavik

*contact time prep time*

Guest Lecturer 35 Graduate 10 hours/year 20 hours/year

Students for 1 year(s) for 1 year(s)

*National*

2012-3 American Association for Cancer Research Integrative Workshop on Molecular Epidemiology

*contact time prep time*

Course Faculty 50 Graduate 40 hours/year 80 hours/year

Students for 1 year(s) for 1 year(s)

**b. Invited Presentations**

**Invited Lecture and Symposium Panelist/Speaker**

*International*

2004 Tissue Microarrays in Cancer Epidemiology, 2004 Hydra

Cancer Meeting, Hydra, Greece

2006 Epidemiological studies on the relationship between acrylamide in the diet and cancer risk, Multidisciplinary approaches to reducing the levels of acrylamide in food, Association of Applied Biologists, Hertfordshire, UK

2007 Panelist, Icelandic Meeting on Prostate Cancer (*Progress*), University of Iceland, Reykjavik, Iceland

2008 Tumor angiogenesis and prostate cancer mortality, University of Orebro, Orebro, Sweden

2008 Concepts and Principles of Cancer Screening, University of Iceland, Reykjavik, Iceland

2008 Panelist, Bladder Cancer-from Pathogenesis to Prevention-International Consultation, World Health Organization International Consultation, Stockholm, Sweden

2009 Panelist, Prostate Cancer Retreat, University of Orebro, Orebro, Sweden

2009 The state of affairs of epidemiological research on acrylamide and human cancer risk, Maastricht University, The Netherlands

2010 Promenade Gruppen: Background and Hypothesis for the randomized trial, Prostate Cancer at Solstice Meeting, University of Iceland, Reykjavik, Iceland

2010 The Patho-Epidemiology of Prostate Cancer: An epidemiologist’s perspective, Società Italiana di Urologia Oncologica (SIURO), Rome, Italy

2010 Symposium Panelist and Speaker, Bologna Patho-epidemiology Prostate Cancer Retreat, University of Bologna, Italy

2010 Nutrigenetics: Antioxidants and SNPs in antioxidant genes in relation to prostate cancer, Neon Annual Meeting, Nobel Forum, Karolinska Institutet, Stockholm, Sweden

2011 Patho-epidemiology studies of molecular signatures in the SPCG-4 trial, Scandinavian Prostate Cancer Group Annual Meeting, Stockholm, Sweden

2011 Molecular Markers of Lethal Prostate Cancer, 9th Annual World Congress of Urological Research, Innsbruck Austria

2011 Shedding Light on the Heritability of Prostate Cancer: a study of 100,000 Nordic Twins, Invited Lecture, Trinity College, Dublin Ireland

2011 Tumor Drivers of the Link Between Obesity and Lethal Prostate Cancer, Research Oncology Seminar, Kings College, London UK

2012 Tumor markers of Lethal Prostate Cancer: Links with Obesity, Faculty Meeting Seminar, Karolinska Institutet, Stockholm, Sweden

2012 Unveiling the heritability in cancer: an updated analysis from the Nordic twin registry of cancer, 14th Congress of the International Society Twin Studies, Florence, Italy

2012 Integrating mRNA profiling in prostate cancer risk prediction, Prostate Cancer UK Action Forum, Rotterdam, the Netherlands

*National*

2004 Dietary acrylamide and risk of cancer, American Chemical

Society, 227th National Meeting in Anaheim, CA

2005 Dietary Acrylamide and risk of human cancer: the role of

epidemiology, Society of Toxicology, 44th Annual Meeting, New Orleans, LA

2006 Identifying molecular signatures of indolent and lethal prostate cancer. Prostate Cancer InterSPORE Meeting, National Cancer Institute, Houston, TX

2007 Multigene signatures of indolent and lethal prostate cancer, Active Surveillance for Early Stage Prostate Cancer, San Francisco, CA

2007 Panelist, The role of acrylamide in diet and risk of cancer, American Chemical Society, 229th National Meeting in Boston, MA

2008 Obesity and the *TMPRSS2:ERG* Fusion, Prostate Cancer Foundation Annual Retreat, Lake Tahoe, CA

2008 Obesity and Prostate Cancer Progression in the Physicians’ Health Study, National Cancer Institute Translational Meeting, Washington DC.

2008 Central adiposity and prostate cancer survival in relation to tumor tissue expression of sex steroid hormone receptors, Tri-institutional Prostate Cancer Program Retreat, Newport, RI

2009 Tomatoes, lycopene and prostate cancer: is the association with disease progression mediated through angiogenesis? Tri-institutional Prostate Cancer Program Retreat, Baltimore, MD

2009 Do antioxidants prevent risk of TMPRSS2:ERG fusion prostate cancer? Prostate Cancer Foundation Annual Scientific Retreat, Lake Tahoe CA

1. Genetic and lifestyle factors impact prostate cancer survival through angiogenesis. 7th Annual International M. Judah Folkman Conference Antiangiogenesis: New Frontiers in Therapeutic Development, Boston, MA

2009 TMPRSS2:ERG fusion and SPINK1 in prostate cancer etiology and progression, National Cancer Institute Translational Meeting, Tyson’s Corner, VA

2010 The patho-epidemiology of prostate cancer. Multi-institutional Prostate Cancer Program Retreat, Ft Lauderdale, FL

1. Genetic variation in antioxidant pathway and prostate cancer progression, SELECT Trial Symposium, Southwest Oncology Group, Dallas, TX
2. Promenadgruppen: a pilot walking intervention among men with prostate cancer. Fourth annual Multi-Institutional Prostate Cancer Program Retreat, Ft. Lauderdale, FL

2012 Session Chair, Prostate Cancer: Risk, Fifth annual Multi-Institutional Prostate Cancer Program Retreat, Ft. Lauderdale, FL

1. Tumor Tissue Collection: The Experience of the Harvard Cohorts. 2011 Annual Meeting of the National Cancer Institute Cohort Consortium, Boston MA

2012 Panelist, Celebration of Science, FasterCures and the Milken Institute, Washington DC

2012 Poster Discussant, American Society for Clinical Oncology Annual Meeting, Genitourinary (Prostate) Cancer, Chicago, Illinois

2013 Session Chair, Prostate Cancer: Risk, Sixth annual Multi-Institutional Prostate Cancer Program Retreat, Ft. Lauderdale, FL

2013 Panelist, Milken Institute Global Conference, Living to 1000: Impossible or in reach?, Beverly Hills, CA

*Regional*

2004 Acid-labile Subunit and Prostate Cancer Risk: A

Prospective Study, Slone Epidemiology Seminar, Boston University School of Public Health, Boston, MA

2005 Identifying Molecular Markers of Indolent and Aggressive

Prostate Cancer, Boston University Medical Grand Rounds, Boston Medical Center, Boston MA

2008 Metabolism and Prostate Cancer in the PHS and HPFS cohorts, Cancer Genome Program, Broad Institute, Cambridge, MA

2011 Keynote Address: Prevention of Lethal Prostate Cancer: opportunities and novel hypotheses. Massachusetts Prostate Cancer Coalition, Newton MA

**b. Professional Leadership Roles related to Teaching**

2005- International Harvard University-Karolinska Institutet

Conference organizer for the first Scandanavian-US Prostate Cancer Summit, held in the Stockholm archipelago in September 2005. Organized scientific agenda and conference participants for this international working group supporting collaborations on prostate cancer research between researchers from leading medical universities in the US (Harvard University, University of Michigan) and Sweden (Karolinska Institutet, Uppsala University, University of Orebro).

2006-10 Director, Channing Peer Mentoring Program

One of three co-directors of peer mentoring program for 40 fellows and instructors affiliated with the Channing Laboratory. Meet fellows individually to provide guidance to optimize the post-doctoral experience, Brigham and Women’s Hospital

2008 Educational Review Panel for MPH and doctoral students at the Division of Public Health Sciences, University of Iceland, Reykjavik

2009 Thesis Examiner for PhD candidate (Janneke Hogervorst), *Dietary acrylamide and human cancer risk,* Maastricht University, Maastricht The Netherlands

2010 Thesis Examiner for PhD candidate (Elizabeth Tindall), *Genetic contributions to inflammatory mediated prostate cancer*, University of New South Wales, Australia

2011-3 Faculty Member, American Association for Cancer Research Integrative Workshop on Molecular Epidemiology

2012 Organizer and Discussion Leader, Risk Session, 5th Multi-Institutional SPORE Meeting, Ft Lauderdale

2012 Organizer and Co-Leader, 6th Annual International Prostate Cancer Patho-Epidemiology Retreat, Martha’s Vineyard

2012 Poster Discussant, American Society for Clinical Oncology Annual Meeting, Genitourinary (Prostate) Cancer, Chicago, Illinois

2013 Organizer and Discussion Leader, Risk Session, 6th Multi-Institutional SPORE Meeting, Ft Lauderdale

**3. Description of Teaching Award(s) Received**

2005 Teaching Commendation

Harvard School of Public Health

**Part III: Bibliography**

**Original Articles**

1. Kuper H, Tzonou A, Lagiou P, **Mucci LA**, Trichopoulos D, Stuver SO and Trichopoulou A. Diet and hepatocellular carcinoma: a case-control study in Greece. Nutr Cancer 2000;38(1):6-12.

2. Signorello LB, Kuper H, Lagiou P, Wuu J, **Mucci LA**, Trichopoulos D and Adami HO. Lifestyle factors and insulin-like growth factor 1 levels among elderly men. Eur J Cancer Prev 2000;9(3):173-8.

3. Hathaway JE, Silverman JG, Aynalem G, **Mucci L** and Brooks DR. Use of medical care, police assistance, and restraining orders by women reporting intimate partner violence--Massachusetts, 1996-1997. MMWR 2000;49(22):485-8.

4. Hathaway JE, **Mucci LA**, Silverman JG, Brooks DR, Mathews R and Pavlos CA. Health status and health care use of Massachusetts women reporting partner abuse. Am J Prev Med 2000;19(4):302-7.

5. Kuper H, Hsieh C, Stuver SO, **Mucci LA**, Tzonou A, Zavitsanos X, Lagiou P and Trichopoulos D. Birth order, as a proxy for age at infection, in the etiology of hepatocellular carcinoma. Epidemiology 2000;11(6):680-3.

6. Petridou E, Giokas G, Kuper H, **Mucci LA** and Trichopoulos D. Endocrine correlates of male breast cancer risk: a case-control study in Athens, Greece. Br J Cancer 2000;83(9):1234-7. PubMed Central PMCID: PMC2363586.

7. Kuper H, Lagiou P, **Mucci LA**, Tamimi R, Benetou V and Trichopoulos D. Risk factors for cholangiocarcinoma in a low risk Caucasian population. Soz Praventivmed 2001;46(3):182-5.

8. Kuper H, Mantzoros C, Lagiou P, Tzonou A, Tamimi R, **Mucci L**, Benetou V, Spanos E, Stuver SO and Trichopoulos D. Estrogens, testosterone and sex hormone binding globulin in relation to liver cancer in men. Oncology 2001;60(4):355-60.

9. Lagiou A, Trichopoulos D, Tzonou A, Lagiou P and **Mucci L**. Are there age-dependent effects of diet on prostate cancer risk? Soz Praventivmed 2001;46(5):329-34.

10. Orner MB, Meehan T, Brooks DR, **Mucci LA** and McGuire JF. Support for condom availability and needle exchange programs among Massachusetts adults, 1997. AIDS Educ Prev 2001;13(4):365-76.

11. Silverman JG, Raj A, **Mucci LA** and Hathaway JE. Dating violence against adolescent girls and associated substance use, unhealthy weight control, sexual risk behavior, pregnancy, and suicidality. JAMA 2001;286(5):572-9.

12. Brooks DR and **Mucci LA**. Support for smoke-free restaurants among Massachusetts adults, 1992-1999. Am J Public Health 2001;91(2):300-3. PubMed Central PMCID: PMC1446536.

13. Weiderpass E, Ye W, **Mucci LA**, Nyren O, Trichopoulos D, Vainio H and Adami HO. Alcoholism and risk for endometrial cancer. Int J Cancer 2001;93(2):299-301.

14. **Mucci LA** and Brooks DR. Lower use of dental services among long term cigarette smokers. J Epidemiol Community Health 2001;55(6):389-93. PubMed Central PMCID: PMC1731911.

15. **Mucci LA**, Tamimi R, Lagiou P, Trichopoulou A, Benetou V, Spanos E and Trichopoulos D. Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int 2001;87(9):814-20.

16. Tamimi R, **Mucci LA**, Spanos E, Lagiou A, Benetou V and Trichopoulos D. Testosterone and oestradiol in relation to tobacco smoking, body mass index, energy consumption and nutrient intake among adult men. Eur J Cancer Prev 2001;10(3):275-80.

17. **Mucci LA**, Kuper HE, Tamimi R, Lagiou P, Spanos E and Trichopoulos D. Age at menarche and age at menopause in relation to hepatocellular carcinoma in women. BJOG 2001;108(3):291-4.

18. Demissie S, Green RC, **Mucci L**, Tziavas S, Martelli K, Bang K, Coons L, Bourque S, Buchillon D, Johnson K, Smith T, Sharrow N, Lautenschlager N, Friedland R, Cupples LA and Farrer LA. Reliability of information collected by proxy in family studies of Alzheimer's disease. Neuroepidemiology 2001;20(2):105-11.

19. Kuper H, Ye W, Broome U, Romelsjo A, **Mucci LA**, Ekbom A, Adami HO, Trichopoulos D and Nyren O. The risk of liver and bile duct cancer in patients with chronic viral hepatitis, alcoholism, or cirrhosis. Hepatology 2001;34(4 Pt 1):714-8.

20. Boffetta P, Ye W, Adami HO, **Mucci LA** and Nyren O. Risk of cancers of the lung, head and neck in patients hospitalized for alcoholism in Sweden. Br J Cancer 2001;85(5):678-82. PubMed Central PMCID: PMC2364115.

21. Lagiou P, Tamimi R, Lagiou A, **Mucci L** and Trichopoulos D. Is epidemiology implicating extremely low frequency electric and magnetic fields in childhood leukemia? Environ Health Prev Med 2002;7(2):33-9. PubMed Central PMCID: PMC2723397.

22. Lagiou P, Hsieh CC, Trichopoulos D, Xu B, Wuu J, **Mucci L**, Tamimi R, Adami HO and Cnattingius S. Birthweight differences between USA and China and their relevance to breast cancer aetiology. Int J Epidemiol 2003;32(2):193-8.

23. Lagiou P, Tamimi R, **Mucci LA**, Trichopoulos D, Adami HO and Hsieh CC. Nausea and vomiting in pregnancy in relation to prolactin, estrogens, and progesterone: a prospective study. Obstet Gynecol 2003;101(4):639-44.

24. **Mucci L**, Dickman PW, Steineck G, Adami HO and Augustsson K. Reply: Dietary acrylamide and cancer risk: additional data on coffee. Br J Cancer 2003;89(4):775-6.

25. **Mucci LA**, Dickman PW, Steineck G, Adami HO and Augustsson K. Dietary acrylamide and cancer of the large bowel, kidney, and bladder: absence of an association in a population-based study in Sweden. Br J Cancer 2003;88(1):84-9. PubMed Central PMCID: PMC2376776.

26. Tamimi R, Lagiou P, Vatten LJ, **Mucci L**, Trichopoulos D, Hellerstein S, Ekbom A, Adami HO and Hsieh CC. Pregnancy hormones, pre-eclampsia, and implications for breast cancer risk in the offspring. Cancer Epidemiol Biomarkers Prev 2003;12(7):647-50.

27. Brawarsky P, Brooks DR and **Mucci LA**. Correlates of colorectal cancer testing in Massachusetts men and women. Prev Med 2003;36(6):659-68.

28. Tamimi RM, Lagiou P, **Mucci LA**, Hsieh CC, Adami HO and Trichopoulos D. Average energy intake among pregnant women carrying a boy compared with a girl. BMJ 2003;326(7401):1245-6. PubMed Central PMCID: PMC161555.

29. **Mucci LA**, Lagiou P, Tamimi RM, Hsieh CC, Adami HO and Trichopoulos D. Pregnancy estriol, estradiol, progesterone and prolactin in relation to birth weight and other birth size variables (United States). Cancer Causes Control 2003;14(4):311-8.

30. Brawarsky P, Brooks DR, **Mucci LA** and Wood PA. Effect of physician recommendation and patient adherence on rates of colorectal cancer testing. Cancer Detect Prev 2004;28(4):260-8.

31. Brooks DR, **Mucci LA**, Hatch EE and Cnattingius S. Maternal smoking during pregnancy and risk of brain tumors in the offspring. A prospective study of 1.4 million Swedish births. Cancer Causes Control 2004;15(10):997-1005.

32. Lagiou P, Tamimi RM, **Mucci LA**, Adami HO, Hsieh CC and Trichopoulos D. Diet during pregnancy in relation to maternal weight gain and birth size. Eur J Clin Nutr 2004;58(2):231-7.

33. **Mucci LA**, Hsieh CC, Williams PL, Dickman PW, Bjorkman L and Pedersen NL. Birth order, sibship size, and housing density in relation to tooth loss and periodontal disease: a cohort study among Swedish twins. Am J Epidemiol 2004;159(5):499-506.

34. **Mucci LA**, Lindblad P, Steineck G and Adami HO. Dietary acrylamide and risk of renal cell cancer. Int J Cancer 2004;109(5):774-6.

35. **Mucci LA**, Granath F and Cnattingius S. Maternal smoking and childhood leukemia and lymphoma risk among 1,440,542 Swedish children. Cancer Epidemiol Biomarkers Prev 2004;13(9):1528-33.

36. **Mucci LA**, Lagiou P, Hsieh CC, Tamimi R, Hellerstein S, Vatten L, Adami HO, Cnattingius S and Trichopoulos D. A prospective study of pregravid oral contraceptive use in relation to fetal growth. BJOG 2004;111(9):989-95.

37. Badovinac RL, Morgan KE, Lefevre J, Wadhawan S, **Mucci L**, Schoeff L and Douglass CW. Risk assessment criteria applied to a screening exam: implications for improving the efficiency of a sealant program. J Public Health Dent 2005;65(4):203-8.

38. Lagiou P, **Mucci L**, Tamimi R, Kuper H, Lagiou A, Hsieh CC and Trichopoulos D. Micronutrient intake during pregnancy in relation to birth size. Eur J Nutr 2005;44(1):52-9.

39. Margolis KL, **Mucci L**, Braaten T, Kumle M, Trolle Lagerros Y, Adami HO, Lund E and Weiderpass E. Physical activity in different periods of life and the risk of breast cancer: the Norwegian-Swedish Women's Lifestyle and Health cohort study. Cancer Epidemiol Biomarkers Prev 2005;14(1):27-32.

40. Bradbury BD, Brooks DR, Brawarsky P and **Mucci LA**. Test-retest reliability of colorectal testing questions on the Massachusetts Behavioral Risk Factor Surveillance System (BRFSS). Prev Med 2005;41(1):303-11.

41. Rubin MA, Bismar TA, Andren O, **Mucci L**, Kim R, Shen R, Ghosh D, Wei JT, Chinnaiyan AM, Adami HO, Kantoff PW and Johansson JE. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005;14(6):1424-32.

42. **Mucci LA**, Sandin S, Balter K, Adami HO, Magnusson C and Weiderpass E. Acrylamide intake and breast cancer risk in Swedish women. JAMA 2005;293(11):1326-7.

43. Trolle-Lagerros Y, **Mucci LA**, Kumle M, Braaten T, Weiderpass E, Hsieh CC, Sandin S, Lagiu P, Trichopoulos D, Lund E and Adami HO. Physical activity as a determinant of mortality in women. Epidemiology 2005;16(6):780-5.

44. **Mucci LA**, Bjorkman L, Douglass CW and Pedersen NL. Environmental and heritable factors in the etiology of oral diseases--a population-based study of Swedish twins. J Dent Res 2005;84(9):800-5.

45. Lagerros YT, **Mucci LA**, Bellocco R, Nyren O, Balter O and Balter KA. Validity and reliability of self-reported total energy expenditure using a novel instrument. Eur J Epidemiol 2006;21(3):227-36.

46. Lagiou P, Trichopoulos D, Sandin S, Lagiou A, **Mucci L**, Wolk A, Weiderpass E and Adami HO. Mediterranean dietary pattern and mortality among young women: a cohort study in Sweden. Br J Nutr 2006;96(2):384-92.

47. **Mucci LA**, Adami HO and Wolk A. Prospective study of dietary acrylamide and risk of colorectal cancer among women. Int J Cancer 2006;118(1):169-73.

48. Clements KM, Cohen BB, Brawarsky P, Brooks DR, **Mucci LA** and Wood PA. Identifying Health Maintenance Organization membership through self-report of health plan name: ascertainment and reliability. J Public Health Manag Pract 2006;12(3):278-87.

49. **Mucci LA**, Wood PA, Cohen B, Clements KM, Brawarsky P and Brooks DR. Validity of self-reported health plan information in a population-based health survey. J Public Health Manag Pract 2006;12(6):570-7.

50. Hunt H, Valdimarsdottir U, **Mucci L**, Kreicbergs U and Steineck G. When death appears best for the child with severe malignancy: a nationwide parental follow-up. Palliat Med 2006;20(6):567-77.

51. Lagiou P, Sandin S, Weiderpass E, Lagiou A, **Mucci L**, Trichopoulos D and Adami HO. Low carbohydrate-high protein diet and mortality in a cohort of Swedish women. J Intern Med 2007;261(4):366-74.

52. Bakaysa SL, **Mucci LA**, Slagboom PE, Boomsma DI, McClearn GE, Johansson B and Pedersen NL. Telomere length predicts survival independent of genetic influences. Aging Cell 2007;6(6):769-74.

53. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, **Mucci LA**, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE and Rubin MA. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26(31):4596-9.

54. Li H, Stampfer MJ, Hollis JB, **Mucci LA**, Gaziano JM, Hunter D, Giovannucci EL and Ma J. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 2007;4(3):e103. PubMed Central PMCID: PMC1831738.

55. Baik I, Lambe M, Liu Q, Cnattingius S, **Mucci LA**, Riman T, Ekbom A, Adami HO and Hsieh CC. Gender of offspring and maternal risk of invasive epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2007;16(11):2314-20.

56. McIntyre MH, Kantoff PW, Stampfer MJ, **Mucci LA**, Parslow D, Li H, Gaziano JM, Abe M and Ma J. Prostate cancer risk and ESR1 TA, ESR2 CA repeat polymorphisms. Cancer Epidemiol Biomarkers Prev 2007;16(11):2233-6.

57. **Mucci LA**, Dickman PW, Lambe M, Adami HO, Trichopoulos D, Riman T, Hsieh CC and Cnattingius S. Gestational age and fetal growth in relation to maternal ovarian cancer risk in a Swedish cohort. Cancer Epidemiol Biomarkers Prev 2007;16(9):1828-32. PubMed Central PMCID: PMC2646123.

58. Andren O, Fall K, Andersson SO, Rubin MA, Bismar TA, Karlsson M, Johansson JE and **Mucci LA**. MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer 2007;97(6):730-4. PubMed Central PMCID: PMC2360377.

59. **Mucci LA** and Wilson KM. Acrylamide intake through diet and human cancer risk. J Agric Food Chem 2008;56(15):6013-9.

60. Baik I, Lambe M, Liu Q, Chie L, Cnattingius S, **Mucci LA**, Riman T, Ekbom A, Adami HO and Hsieh CC. Birth spacing and maternal risk of invasive epithelial ovarian cancer in a Swedish nationwide cohort. Cancer Causes Control 2008;19(10):1131-7. PubMed Central PMCID: PMC3221393.

61. Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di Vizio D, Priolo C, Sharma C, Xie W, Hemler ME, **Mucci L**, Giovannucci E, Finn S and Loda M. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest 2008;88(12):1340-8. PubMed Central PMCID: PMC3223737.

62. Sarzani R, Marcucci P, Salvi F, Bordicchia M, Espinosa E, **Mucci L**, Lorenzetti B, Minardi D, Muzzonigro G, Dessi-Fulgheri P and Rappelli A. Angiotensin II stimulates and atrial natriuretic peptide inhibits human visceral adipocyte growth. Int J Obes (Lond) 2008;32(2):259-67.

63. **Mucci LA**, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Andersson SO, Andren O, Eisenstein AS, Holmberg L, Huang W, Kantoff PW, Perner S, Stampfer MJ, Johansson JE and Rubin MA. Nine-gene molecular signature is not associated with prostate cancer death in a watchful waiting cohort. Cancer Epidemiol Biomarkers Prev 2008;17(1):249-51.

64. **Mucci LA**, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Andersson SO, Andren O, Eisenstein A, Holmberg L, Huang W, Kantoff PW, Kim R, Perner S, Stampfer MJ, Johansson JE and Rubin MA. Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev 2008;17(7):1682-8. PubMed Central PMCID: PMC2536630.

65. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andren O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, **Mucci LA**, Kantoff PW, Stampfer MJ, Andersson SO, Varenhorst E, Johansson JE, Brown M, Golub TR and Rubin MA. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008;100(11):815-25. PubMed Central PMCID: PMC3073404.

66. Ma J, Li H, Giovannucci E, **Mucci L**, Qiu W, Nguyen PL, Gaziano JM, Pollak M and Stampfer MJ. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008;9(11):1039-47. PubMed Central PMCID: PMC2651222.

67. Jesser C, **Mucci L**, Farmer D, Moon C, Li H, Gaziano JM, Stampfer M, Ma J and Kantoff P. Effects of G/A polymorphism, rs266882, in the androgen response element 1 of the PSA gene on prostate cancer risk, survival and circulating PSA levels. Br J Cancer 2008;99(10):1743-7. PubMed Central PMCID: PMC2584945.

68. Cnattingius S, Eloranta S, Adami HO, Axelsson O, Dickman PW, Hsieh CC, **Mucci LA**, Trichopoulos D, Lambe M and Johansson AL. Placental weight and risk of invasive epithelial ovarian cancer with an early age of onset. Cancer Epidemiol Biomarkers Prev 2008;17(9):2344-9. PubMed Central PMCID: PMC2643070.

69. Fall K, Stark JR, **Mucci LA**, Chan J, Stampfer MJ, Kurth T, Febbo PG, Kantoff P and Ma J. No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk. Prostate 2008;68(13):1416-20. PubMed Central PMCID: PMC2958090.

70. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, **Mucci L**, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S and Loda M. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 2009;101(7):519-32. PubMed Central PMCID: PMC2664091.

71. Wilson KM, **Mucci LA**, Cho E, Hunter DJ, Chen WY and Willett WC. Dietary acrylamide intake and risk of premenopausal breast cancer. Am J Epidemiol 2009;169(8):954-61. PubMed Central PMCID: PMC2727226.

72. Fall K, Fang F, **Mucci LA**, Ye W, Andren O, Johansson JE, Andersson SO, Sparen P, Klein G, Stampfer M, Adami HO and Valdimarsdottir U. Immediate risk for cardiovascular events and suicide following a prostate cancer diagnosis: prospective cohort study. PLoS Med 2009;6(12):e1000197. PubMed Central PMCID: PMC2784954.

73. Dhillon PK, Barry M, Stampfer MJ, Perner S, Fiorentino M, Fornari A, Ma J, Fleet J, Kurth T, Rubin MA and **Mucci LA**. Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2009;18(2):595-600. PubMed Central PMCID: PMC2692093.

74. Andren O, Garmo H, **Mucci L**, Andersson SO, Johansson JE and Fall K. Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer 2009;100(1):170-3. PubMed Central PMCID: PMC2634678.

75. Holmberg L, Adolfsson J, **Mucci L**, Garmo H, Adami HO, Moller H, Johansson JE and Stampfer M. Season of diagnosis and prognosis in breast and prostate cancer. Cancer Causes Control 2009;20(5):663-70.

76. Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, **Mucci L**, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S and Freedman ML. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res 2009;69(13):5568-74. PubMed Central PMCID: PMC2884104.

77. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA and **Mucci LA**. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 2009;27(21):3459-64. PubMed Central PMCID: PMC2717753.

78. Stark JR, Wiklund F, Gronberg H, Schumacher F, Sinnott JA, Stampfer MJ, **Mucci LA** and Kraft P. Toll-like receptor signaling pathway variants and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2009;18(6):1859-63. PubMed Central PMCID: PMC2833418.

79. Stark JR, Li H, Kraft P, Kurth T, Giovannucci EL, Stampfer MJ, Ma J and **Mucci LA**. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer 2009;124(11):2683-9. PubMed Central PMCID: PMC2667697.

80. Liu C, Wang XD, **Mucci L**, Gaziano JM and Zhang SM. Modulation of lung molecular biomarkers by beta-carotene in the Physicians' Health Study. Cancer 2009;115(5):1049-58. PubMed Central PMCID: PMC2649969.

81. Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, **Mucci L**, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ and Freedman ML. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res 2009;15(9):3223-30. PubMed Central PMCID: PMC2878092.

82. **Mucci LA** and Adami HO. The plight of the potato: is dietary acrylamide a risk factor for human cancer? J Natl Cancer Inst 2009;101(9):618-21.

83. Wilson KM, Balter K, Adami HO, Gronberg H, Vikstrom AC, Paulsson B, Tornqvist M and **Mucci LA**. Acrylamide exposure measured by food frequency questionnaire and hemoglobin adduct levels and prostate cancer risk in the Cancer of the Prostate in Sweden Study. Int J Cancer 2009;124(10):2384-90. PubMed Central PMCID: PMC2905318.

84. **Mucci LA**, Powolny A, Giovannucci E, Liao Z, Kenfield SA, Shen R, Stampfer MJ and Clinton SK. Prospective study of prostate tumor angiogenesis and cancer-specific mortality in the health professionals follow-up study. J Clin Oncol 2009;27(33):5627-33. PubMed Central PMCID: PMC2792955.

85. Stark JR, Judson G, Alderete JF, Mundodi V, Kucknoor AS, Giovannucci EL, Platz EA, Sutcliffe S, Fall K, Kurth T, Ma J, Stampfer MJ and **Mucci LA**. Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study. J Natl Cancer Inst 2009;101(20):1406-11. PubMed Central PMCID: PMC2765259.

86. Kasperzyk JL, Fall K, **Mucci LA**, Hakansson N, Wolk A, Johansson JE, Andersson SO and Andren O. One-carbon metabolism-related nutrients and prostate cancer survival. Am J Clin Nutr 2009;90(3):561-9. PubMed Central PMCID: PMC2728642.

87. **Mucci LA**, Hsieh CC, Williams PL, Arora M, Adami HO, de Faire U, Douglass CW and Pedersen NL. Do genetic factors explain the association between poor oral health and cardiovascular disease? A prospective study among Swedish twins. Am J Epidemiol 2009;170(5):615-21. PubMed Central PMCID: PMC2732988.

88. **Mucci LA**, Stark JR, Figg WD, Schumacher F, Li H, Abe M, Hennessy K, Stampfer MJ, Gaziano JM, Ma J and Kantoff PW. Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study. Int J Cancer 2009;125(5):1143-6. PubMed Central PMCID: PMC2838373.

89. Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami HO, Fall K, **Mucci LA**, Kantoff PW, Stampfer M, Andersson SO, Varenhorst E, Johansson JE, Gerstein MB, Golub TR, Rubin MA and Andren O. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics 2010;3:8. PubMed Central PMCID: PMC2855514.

90. Fiorentino M, Judson G, Penney K, Flavin R, Stark J, Fiore C, Fall K, Martin N, Ma J, Sinnott J, Giovannucci E, Stampfer M, Sesso HD, Kantoff PW, Finn S, Loda M and **Mucci L**. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res 2010;70(8):3136-9. PubMed Central PMCID: PMC3049266.

91. Schumacher FR, Cheng I, Freedman ML, **Mucci L**, Allen NE, Pollak MN, Hayes RB, Stram DO, Canzian F, Henderson BE, Hunter DJ, Virtamo J, Manjer J, Gaziano JM, Kolonel LN, Tjonneland A, Albanes D, Calle EE, Giovannucci E, Crawford ED, Haiman CA, Kraft P, Willett WC, Thun MJ, Le Marchand L, Kaaks R, Feigelson HS, Bueno-de-Mesquita HB, Palli D, Riboli E, Lund E, Amiano P, Andriole G, Dunning AM, Trichopoulos D, Stampfer MJ, Key TJ and Ma J. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet 2010;19(15):3089-101. PubMed Central PMCID: PMC2901143.

92. **Mucci LA**, Stark JR, Pollak MN, Li H, Kurth T, Stampfer MJ and Ma J. Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev 2010;19(2):484-91. PubMed Central PMCID: PMC2820127.

93. Li H, Stampfer MJ, **Mucci L**, Rifai N, Qiu W, Kurth T and Ma J. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. Clin Chem 2010;56(1):34-43. PubMed Central PMCID: PMC2858593.

94. Arora M, Weuve J, Fall K, Pedersen NL and **Mucci LA**. An exploration of shared genetic risk factors between periodontal disease and cancers: a prospective co-twin study. Am J Epidemiol 2010;171(2):253-9. PubMed Central PMCID: PMC2878098.

95. Vikstrom AC, Wilson KM, Paulsson B, Athanassiadis I, Gronberg H, Adami HO, Adolfsson J, **Mucci LA**, Balter K and Tornqvist M. Alcohol influence on acrylamide to glycidamide metabolism assessed with hemoglobin-adducts and questionnaire data. Food Chem Toxicol 2010;48(3):820-4.

96. Fang F, Keating NL, **Mucci LA**, Adami HO, Stampfer MJ, Valdimarsdottir U and Fall K. Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States. J Natl Cancer Inst 2010;102(5):307-14.

97. Penney KL, Schumacher FR, Li H, Kraft P, Morris JS, Kurth T, **Mucci LA**, Hunter DJ, Kantoff PW, Stampfer MJ and Ma J. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila) 2010;3(5):604-10. PubMed Central PMCID: PMC2865569.

98. Penney KL, Pyne S, Schumacher FR, Sinnott JA, **Mucci LA**, Kraft PL, Ma J, Oh WK, Kurth T, Kantoff PW, Giovannucci EL, Stampfer MJ, Hunter DJ and Freedman ML. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2010;19(11):2869-76. PubMed Central PMCID: PMC3197738.

99. Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, **Mucci LA**, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC and Freedman ML. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet 2010;6(11):e1001204. PubMed Central PMCID: PMC2978684.

100. Fang F, Valdimarsdottir U, **Mucci L**, Sparen P, Ye W and Fall K. Hospitalization for osteoarthritis and prostate cancer specific mortality among Swedish men with prostate cancer. Cancer Epidemiol 2010;34(5):644-7.

101. Wilson KM, **Mucci LA**, Rosner BA and Willett WC. A prospective study on dietary acrylamide intake and the risk for breast, endometrial, and ovarian cancers. Cancer Epidemiol Biomarkers Prev 2010;19(10):2503-15. PubMed Central PMCID: PMC2952046.

102. Meyer MS, **Mucci LA**, Andersson SO, Andren O, Johansson JE, Tretli S and Adami HO. Homogeneous prostate cancer mortality in the Nordic countries over four decades. Eur Urol 2010;58(3):427-32. PubMed Central PMCID: PMC2936655.

103. Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, Fiorentino M, Finn S, Flavin RJ, Kurth T, Price AL, Giovannucci EL, Fall K, Stampfer MJ, Ma J and **Mucci LA**. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis 2010;31(9):1597-603. PubMed Central PMCID: PMC2930803.

104. Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, Fiore C, Qiu W, Fiorentino M, Finn S, Penney KL, Eisenstein A, Schumacher FR, **Mucci LA**, Stampfer MJ, Giovannucci E and Loda M. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol 2010;28(25):3958-64. PubMed Central PMCID: PMC2940394.

105. Fang F, Kasperzyk JL, Shui I, Hendrickson W, Hollis BW, Fall K, Ma J, Gaziano JM, Stampfer MJ, **Mucci LA** and Giovannucci E. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One 2011;6(4):e18625. PubMed Central PMCID: PMC3071841.

106. Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, Fiorentino M, Finn S, Loda M, Rifai N, **Mucci LA**, Giovannucci E, Stampfer MJ and Ma J. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2011;20(12):2618-27.

107. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott KL, Signoretti S, Bardeesy N, Wang YA, Hill DE, Golub TR, Stampfer MJ, Wong WH, Loda M, **Mucci L**, Chin L and DePinho RA. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011;470(7333):269-73.

108. Penney KL, Schumacher FR, Kraft P, **Mucci LA**, Sesso HD, Ma J, Niu Y, Cheong JK, Hunter DJ, Stampfer MJ and Hsu SI. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis 2011;32(6):853-9. PubMed Central PMCID: PMC3106437.

109. Wilson KM, Kasperzyk JL, Rider JR, Kenfield S, van Dam RM, Stampfer MJ, Giovannucci E and **Mucci LA**. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst 2011;103(11):876-84. PubMed Central PMCID: PMC3110172.

110. Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, Fiore C, Penney KL, Ma J, Kantoff PW, Stampfer MJ, Loda M, **Mucci LA** and Giovannucci E. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol 2011;29(17):2378-85. PubMed Central PMCID: PMC3107752.

111. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark JR, Fiorentino M, Perner S, Finn S, Calza S, Flavin R, Freedman ML, Setlur S, Sesso HD, Andersson SO, Martin N, Kantoff PW, Johansson JE, Adami HO, Rubin MA, Loda M, Golub TR, Andren O, Stampfer MJ and **Mucci LA**. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol 2011;29(17):2391-6. PubMed Central PMCID: PMC3107753.

112. Epstein MM, Kasperzyk JL, Andren O, Giovannucci EL, Wolk A, Hakansson N, Andersson SO, Johansson JE, Fall K and **Mucci LA**. Dietary zinc and prostate cancer survival in a Swedish cohort. Am J Clin Nutr 2011;93(3):586-93. PubMed Central PMCID: PMC3041600.

113. Kasperzyk JL, Shappley WV, 3rd, Kenfield SA, **Mucci LA**, Kurth T, Ma J, Stampfer MJ and Sanda MG. Watchful waiting and quality of life among prostate cancer survivors in the Physicians' Health Study. J Urol 2011;186(5):1862-7. PubMed Central PMCID: PMC3491639.

114. Davidsson S, Fiorentino M, Andren O, Fang F, **Mucci LA**, Varenhorst E, Fall K and Rider JR. Inflammation, focal atrophic lesions, and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 2011;20(10):2280-7. PubMed Central PMCID: [PMC3671592](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671592/?tool=nihms" \t "aux" \o "PMC: #3671592).

115. Epstein MM, Andren O, Kasperzyk JL, Shui IM, Penney KL, Fall K, Rider JR, Stampfer MJ, Andersson SO, Giovannucci E and **Mucci LA**. Seasonal variation in expression of markers in the vitamin D pathway in prostate tissue. Cancer Causes Control 2012;23(8):1359-66. PubMed Central PMCID: PMC3589913.

116. Epstein MM, Kasperzyk JL, **Mucci LA**, Giovannucci E, Price A, Wolk A, Hakansson N, Fall K, Andersson SO and Andren O. Dietary fatty acid intake and prostate cancer survival in Orebro County, Sweden. Am J Epidemiol 2012;176(3):240-52. PubMed Central PMCID: PMC3491963.

117. Etzioni R, **Mucci L**, Chen S, Johansson JE, Fall K and Adami HO. Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Clin Cancer Res 2012;18(24):6742-7.

118. Barry M, Dhillon PK, Stampfer MJ, Perner S, Ma J, Giovannucci E, Kurth T, **Mucci LA** and Rubin MA. alpha-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study. Prostate 2012;72(3):301-6. PubMed Central PMCID: PMC3267640.

119. Wang S, Wu J, Suburu J, Gu Z, Cai J, Axanova LS, Cramer SD, Thomas MJ, Perry DL, Edwards IJ, **Mucci LA**, Sinnott JA, Loda MF, Sui G, Berquin IM and Chen YQ. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer. Carcinogenesis 2012;33(2):404-12. PubMed Central PMCID: PMC3271270.

120. Shui IM, Stark JR, Penney KL, Schumacher FR, Epstein MM, Pitt MJ, Stampfer MJ, Tamimi RM, Lindstrom S, Sesso HD, Fall K, Ma J, Kraft P, Giovannucci E and **Mucci LA**. Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate 2012;72(2):209-16. PubMed Central PMCID: PMC3175021.

121. Torfadottir JE, Steingrimsdottir L, **Mucci L**, Aspelund T, Kasperzyk JL, Olafsson O, Fall K, Tryggvadottir L, Harris TB, Launer L, Jonsson E, Tulinius H, Stampfer M, Adami HO, Gudnason V and Valdimarsdottir UA. Milk intake in early life and risk of advanced prostate cancer. Am J Epidemiol 2012;175(2):144-53. PubMed Central PMCID: PMC3249408.

122. Wilson KM, Giovannucci E, Stampfer MJ and **Mucci LA**. Dietary acrylamide and risk of prostate cancer. Int J Cancer 2012;131(2):479-87. PubMed Central PMCID: PMC3320687.

123. Torfadottir JE, Valdimarsdottir UA, **Mucci L**, Stampfer M, Kasperzyk JL, Fall K, Tryggvadottir L, Aspelund T, Olafsson O, Harris TB, Jonsson E, Tulinius H, Adami HO, Gudnason V and Steingrimsdottir L. Rye bread consumption in early life and reduced risk of advanced prostate cancer. Cancer Causes Control 2012;23(6):941-50. PubMed Central PMCID: PMC3568695.

124. Pettersson A, Kasperzyk JL, Kenfield SA, Richman EL, Chan JM, Willett WC, Stampfer MJ, **Mucci LA** and Giovannucci EL. Milk and dairy consumption among men with prostate cancer and risk of metastases and prostate cancer death. Cancer Epidemiol Biomarkers Prev 2012;21(3):428-36. PubMed Central PMCID: PMC3297731.

125. Margalit DN, Kasperzyk JL, Martin NE, Sesso HD, Gaziano JM, Ma J, Stampfer MJ and **Mucci LA**. Beta-carotene antioxidant use during radiation therapy and prostate cancer outcome in the Physicians' Health Study. Int J Radiat Oncol Biol Phys 2012;83(1):28-32. PubMed Central PMCID: PMC3386602.

126. Shui IM, **Mucci LA**, Kraft P, Tamimi RM, Lindstrom S, Penney KL, Nimptsch K, Hollis BW, Dupre N, Platz EA, Stampfer MJ and Giovannucci E. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst 2012;104(9):690-9. PubMed Central PMCID: PMC3341310.

127. Penney KL, Li H, **Mucci LA**, Loda M, Sesso HD, Stampfer MJ and Ma J. Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate 2012;73(7):700-5.

128. Moller E, Galeone C, Adami HO, Adolfsson J, Andersson TM, Bellocco R, Gronberg H, **Mucci LA** and Balter K. The Nordic Nutrition Recommendations and prostate cancer risk in the Cancer of the Prostate in Sweden (CAPS) study. Public Health Nutr 2012;15(10):1897-908.

129. Pettersson A, Graff RE, Bauer SR, Pitt MJ, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer MJ, Fiorentino M, Kantoff PW, Sanda MG, Giovannucci EL, Ding EL, Loda M and **Mucci LA**. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21(9):1497-509. PubMed Central PMCID: PMC[3671609](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671609/?tool=nihms" \t "aux" \o "PMC: #3671609).

130. Epstein MM, Edgren G, Rider JR, **Mucci LA** and Adami HO. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst 2012;104(17):1335-42. PubMed Central PMCID: PMC3529593.

131. Song Y, Chavarro JE, Cao Y, Qiu W, **Mucci L**, Sesso HD, Stampfer MJ, Giovannucci E, Pollak M, Liu S and Ma J. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. J Nutr 2013;143(2):189-96. PubMed Central PMCID: PMC3542910.

132. Shui IM, **Mucci LA**, Wilson KM, Kraft P, Penney KL, Stampfer MJ and Giovannucci E. Common genetic variation of the calcium-sensing receptor and lethal prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2013;22(1):118-26. PubMed Central PMCID: PMC3538912.

133. Gershman B, Shui IM, Stampfer M, Platz EA, Gann PH, Sesso HL, Dupre N, Giovannucci E and **Mucci LA**. Prediagnostic Circulating Sex Hormones Are Not Associated with Mortality for Men with Prostate Cancer. Eur Urol 2013 Jan 11. pii: S0302-2838(13)00006-7. PubMed Central PMCID: PMC3664134.

134. Preston MA, Harisinghani MG, **Mucci L**, Witiuk K and Breau RH. Diagnostic tests in urology: magnetic resonance imaging (MRI) for the staging of prostate cancer. BJU Int 2013;111(3):514-7.

135. Cai C, Wang H, He HH, Chen S, He L, Ma F, **Mucci L**, Wang Q, Fiore C, Sowalsky AG, Loda M, Liu XS, Brown M, Balk SP and Yuan X. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest 2013;123(3):1109-22. PubMed Central PMCID: PMC3582143.

136. Baena E, Shao Z, Linn DE, Glass K, Hamblen MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, Bronson RT, **Mucci LA**, Loda M, Yuan GC, Orkin SH and Li Z. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev 2013;27(6):683-98. PubMed Central PMCID: PMC3613614.

137. Schoenfeld JD, Margalit DN, Kasperzyk JL, Shui IM, Rider JR, Epstein MM, Meisner A, Kenfield SA, Martin NE, Nguyen PL, Kantoff PW, Giovannucci EL, Stampfer MJ and **Mucci LA**. A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer. Clin Cancer Res 2013;19(6):1612-9. PubMed Central PMCID: PMC3602407.

138. Park HS, Schoenfeld JD, Mailhot RB, Shive M, Hartman RI, Ogembo R and **Mucci LA**. Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann Oncol 2013 Mar 18.

139. Sigurdardottir LG, Valdimarsdottir UA, **Mucci LA**, Fall K, Rider JR, Schernhammer E, Czeisler CA, Launer L, Harris T, Stampfer MJ, Gudnason V, Lockley SW. [Sleep disruption among older men and risk of prostate cancer.](http://www.ncbi.nlm.nih.gov/pubmed/23652374) Cancer Epidemiol Biomarkers Prev. 2013; 22(5):872-9.

140. Torfadottir JE, Valdimarsdottir UA, **Mucci LA**, Kasperzyk JL, Fall K, Tryggvadottir L, Aspelund T, Olafsson O, Harris TB, Jonsson E, Tulinius H, Gudnason V, Adami HO, Stampfer M, Steingrimsdottir L. [Consumption of Fish Products across the Lifespan and Prostate Cancer Risk.](http://www.ncbi.nlm.nih.gov/pubmed/23613715) PLoS One. 2013 Apr 17;8(4):e59799.

141. Wilson KM, Bälter K, Möller E, Adami HO, Andrén O, Andersson SO, Grönberg H, Mucci LA. [Coffee and risk of prostate cancer incidence and mortality in the Cancer of the Prostate in Sweden Study.](http://www.ncbi.nlm.nih.gov/pubmed/23702886)Cancer Causes Control. 2013 May 24. [Epub ahead of print]

141. Robinson D, Garmo H, Bill-Axelson A, **Mucci L**, Holmberg L, Stattin P. 5α-reductase inhibitors and risk of prostate cancer. Nation-wide, population-based case-control study. British Medical Journal 2013; In Press.

**Proceedings of Meetings**

1. **Mucci LA**, Adami HO. The Role of Epidemiology in Understanding the Relationship Between Dietary Acrylamide and Cancer Risk in Humans. In: Friedman M, Mottram DS. Chemistry and Safety of Acrylamide in Food; 2004; Anaheim, CA. New York: Springer;2005. p. 39-48.
2. Kakizoe T, **Mucci LA**, Albertsen PC, Droller MJ. Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease. Scand J Urology Nephrology 2008;42(s218):191-212.

**Reviews/Editorials**

1. Kuper HE, **Mucci LA** and Trichopoulos D. Coffee, pancreatic cancer and the question of causation. J Epidemiol Community Health 2000;54(9):650-1. PubMed Central PMCID: PMC1731751.

2. **Mucci LA**, Wedren S, Tamimi RM, Trichopoulos D and Adami HO. The role of gene-environment interaction in the aetiology of human cancer: examples from cancers of the large bowel, lung and breast. J Intern Med 2001;249(6):477-93.

3. **Mucci LA** and Adami HO. The role of epidemiology in understanding the relationship between dietary acrylamide and cancer risk in humans. Adv Exp Med Biol 2005;561:39-47.

4. Wilson KM, Rimm EB, Thompson KM and **Mucci L**. Dietary acrylamide and cancer risk in humans: a review. J Verbrauch Lebensm 2006;1(1):19-27.

5. **Mucci LA** and Spiegelman D. Vitamin D and prostate cancer risk--a less sunny outlook? J Natl Cancer Inst 2008;100(11):759-61.

6. Kakizoe T, **Mucci LA**, Albertsen PC and Droller MJ. Screening for bladder cancer: theoretical and practical issues in considering the treated and untreated natural history of the various forms of the disease. Scand J Urol Nephrol Suppl 2008;218:191-212.

7. Stark JR, **Mucci L**, Rothman KJ and Adami HO. Screening for prostate cancer remains controversial. BMJ 2009;339:b3601.

8. Szymanski KM, Wheeler DC and **Mucci LA**. Fish consumption and prostate cancer risk: a review and meta-analysis. Am J Clin Nutr 2010;92(5):1223-33.

9. Martin NE, **Mucci LA**, Loda M and Depinho RA. Prognostic determinants in prostate cancer. Cancer J 2011;17(6):429-37. PubMed Central PMCID: PMC3240856.

10. Sigurdardottir LG, Valdimarsdottir UA, Fall K, Rider JR, Lockley SW, Schernhammer E and **Mucci LA**. Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2012;21(7):1002-11. PubMed Central PMCID: PMC3392423.

11. Wilson KM, Giovannucci EL and **Mucci LA**. Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl 2012;14(3):365-74.

**Book Chapters**

1. **Mucci L** and Adami HO. Oral and pharyngeal cancer. In: HO Adami, D Hunter and D Trichopoulos, editors. Textbook of Cancer Epidemiology, 1 ed. New York: Oxford University Press; 2002. p. 115-36.

2. Brennan P, **Mucci L** and Adami HO. Oral and pharyngeal cancer. In: HO Adami, D Hunter and D Trichopoulos, editors. Textbook of Cancer Epidemiology, 2 ed. New York: Oxford University Press; 2008. p. 155-74.

3. **Mucci L**, Signorello LB and Adami HO. Prostate Cancer. In: HO Adami, D Hunter and D Trichopoulos, editors. Textbook of Cancer Epidemiology, 2 ed. New York: Oxford University Press; 2008. p. 517-54.

4. **Mucci L** and Giovannucci E. The role of nutrition and diet in prostate cancer. In: A Bendich and RJ Deckelbaum, editors. Preventive Nutrition: The Comprehensive Guide for Health Professionals, 4 ed. Humana Press; 2009. p. 195-218.

5. Giovannucci E, Platz EA and **Mucci L**. Epidemiology of prostate cancer. In: PT Scardino, WM Linehan, MJ Zelefsky, NJ Vogelzang, BI Rini, BH Bochner and J Sheinfeld, editors. Comprehensive Textbook of Genitourinary Oncology, 4 ed. Baltimore, MD: Lippincott Williams & Filkins; 2011.

**Letters to the Editor**

1. Tamimi R, Trichopoulos D, Lagiou A, **Mucci L**, Adami HO and Hsieh C. Authors' reply: Energy intake in pregnant women carrying boys or girls. BMJ 2003;327(7415):622. PubMed Central PMCID: PMC161555.

2. **Mucci L**, Rimm EB and Thompson KM. Re: Potential Regulatory Action Exempting from the Proposition 65 Warning Requirements, Exposures from Chemicals that form from natural Constituents in Food During cooking or heath Processing. Pesponse to the Office of Environmental Health Hazard Assessment, State of California. 2005.

3. Gershman B, Shui IM, Mucci LA. [Reply from Authors re: Andrea Salonia. Androgens and Prostate Cancer: We Are Still (Almost) Completely Ignorant. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.02.041: Androgens and Prostate Cancer: Clinical Implications and Future Directions.](http://www.ncbi.nlm.nih.gov/pubmed/23562536) Eur Urol. 2013 Mar 19. doi:pii: S0302-2838(13)00252-2.

**Thesis**

1. **Mucci L**. The Epidemiology of Periodontal Disease: Evidence from the Swedish Twin Registry. Boston, MA: Harvard School of Public Health; 2002.